Literature DB >> 29284602

Cervical Cord Atrophy and Long-Term Disease Progression in Patients with Primary-Progressive Multiple Sclerosis.

F X Aymerich1,2, C Auger3, J Alonso3, M Alberich3, J Sastre-Garriga4, M Tintoré4, X Montalban4, A Rovira3.   

Abstract

BACKGROUND AND
PURPOSE: Cervical cord atrophy has been associated with clinical disability in multiple sclerosis and is proposed as an outcome measure of neurodegeneration. The aim of this study was to quantify the development of cervical cord atrophy and to evaluate its association with disability progression in patients with primary-progressive multiple sclerosis.
MATERIALS AND METHODS: Thirty-one patients with primary-progressive multiple sclerosis underwent 1.5T brain and spinal cord MR imaging at baseline and 6-7 years later. The cervical spinal cord from C1 to C5 was segmented to evaluate the normalized overall cross-sectional area and the cross-sectional area of C2-C3, C3-C4, and C4-C5. The annualized rates of normalized cross-sectional area loss were also evaluated. To estimate clinical progression, we determined the Expanded Disability Status Scale score at baseline and at 2 and 14 years after baseline to compute the normalized area under the curve of the Expanded Disability Status Scale and the Expanded Disability Status Scale changes from baseline to the follow-up time points. Associations between the cord cross-sectional area and brain MR imaging and clinical measures were also investigated. Finally, the value of all these measures for predicting long-term disability was evaluated.
RESULTS: Some normalized cross-sectional area measurements showed moderate correlations with the normalized area under the curve of the Expanded Disability Status Scale, ranging from -0.439 to -0.359 (P < .05). Moreover, the annualized rate of the normalized mean cross-sectional area loss and the baseline Expanded Disability Status Scale were independent predictors of long-term disability progression.
CONCLUSIONS: These data indicate that development of cervical cord atrophy is associated with progression of disability and is predictive of this event in patients with primary-progressive MS.
© 2018 by American Journal of Neuroradiology.

Entities:  

Mesh:

Year:  2017        PMID: 29284602      PMCID: PMC7410598          DOI: 10.3174/ajnr.A5495

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  23 in total

1.  Improved MRI quantification of spinal cord atrophy in multiple sclerosis.

Authors:  Hugh Kearney; Marios C Yiannakas; Khaled Abdel-Aziz; Claudia A M Wheeler-Kingshott; Daniel R Altmann; Olga Ciccarelli; David H Miller
Journal:  J Magn Reson Imaging       Date:  2013-04-30       Impact factor: 4.813

2.  Cervical spinal cord volume loss is related to clinical disability progression in multiple sclerosis.

Authors:  Carsten Lukas; Dirk L Knol; Madeleine H Sombekke; Barbara Bellenberg; Horst K Hahn; Veronica Popescu; Katrin Weier; Ernst W Radue; Achim Gass; Ludwig Kappos; Yvonne Naegelin; Bernard M J Uitdehaag; Jeroen J G Geurts; Frederik Barkhof; Hugo Vrenken
Journal:  J Neurol Neurosurg Psychiatry       Date:  2014-06-27       Impact factor: 10.154

3.  Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subtypes and symptoms.

Authors:  G J Nijeholt; M A van Walderveen; J A Castelijns; J H van Waesberghe; C Polman; P Scheltens; P F Rosier; P J Jongen; F Barkhof
Journal:  Brain       Date:  1998-04       Impact factor: 13.501

4.  Large-scale, multicentre, quantitative MRI study of brain and cord damage in primary progressive multiple sclerosis.

Authors:  Marco Rovaris; Elda Judica; Jaume Sastre-Garriga; Alex Rovira; Maria Pia Sormani; Beatrice Benedetti; Tijmen Korteweg; Nicola De Stefano; Zhaleh Khaleeli; Xavier Montalban; Frederik Barkhof; David H Miller; Chris Polman; Alan J Thompson; Massimo Filippi
Journal:  Mult Scler       Date:  2008-01-21       Impact factor: 6.312

5.  Spinal cord atrophy and disability in multiple sclerosis over four years: application of a reproducible automated technique in monitoring disease progression in a cohort of the interferon beta-1a (Rebif) treatment trial.

Authors:  X Lin; C R Tench; B Turner; L D Blumhardt; C S Constantinescu
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-08       Impact factor: 10.154

6.  A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis.

Authors:  X Montalban; J Sastre-Garriga; M Tintoré; L Brieva; F X Aymerich; J Río; J Porcel; C Borràs; C Nos; A Rovira
Journal:  Mult Scler       Date:  2009-09-29       Impact factor: 6.312

7.  Magnetic resonance imaging predictors of disability in primary progressive multiple sclerosis: a 5-year study.

Authors:  V L Stevenson; G T Ingle; D H Miller; A J Thompson
Journal:  Mult Scler       Date:  2004-08       Impact factor: 6.312

8.  Long-term clinical outcome of primary progressive MS: predictive value of clinical and MRI data.

Authors:  J Sastre-Garriga; G T Ingle; M Rovaris; N Téllez; B Jasperse; D R Altmann; B Benedetti; V L Stevenson; M Cercignani; S M Leary; F Barkhof; B Brochet; V Dousset; M Filippi; X Montalban; N F Kalkers; C H Polman; A Rovira; D H Miller; A J Thompson
Journal:  Neurology       Date:  2005-08-23       Impact factor: 9.910

9.  Increasing cord atrophy in early relapsing-remitting multiple sclerosis: a 3 year study.

Authors:  W Rashid; G R Davies; D T Chard; C M Griffin; D R Altmann; R Gordon; A J Thompson; D H Miller
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-01       Impact factor: 10.154

10.  Primary progressive multiple sclerosis: a 5-year clinical and MR study.

Authors:  G T Ingle; V L Stevenson; D H Miller; A J Thompson
Journal:  Brain       Date:  2003-08-05       Impact factor: 13.501

View more
  8 in total

Review 1.  Future Brain and Spinal Cord Volumetric Imaging in the Clinic for Monitoring Treatment Response in MS.

Authors:  Tim Sinnecker; Cristina Granziera; Jens Wuerfel; Regina Schlaeger
Journal:  Curr Treat Options Neurol       Date:  2018-04-20       Impact factor: 3.598

Review 2.  Magnetic resonance imaging in immune-mediated myelopathies.

Authors:  M J Wendebourg; S Nagy; T Derfuss; K Parmar; R Schlaeger
Journal:  J Neurol       Date:  2019-01-29       Impact factor: 4.849

3.  Myelin status is associated with change in functional mobility following slope walking in people with multiple sclerosis.

Authors:  E M King; M J Sabatier; M Hoque; T M Kesar; D Backus; M R Borich
Journal:  Mult Scler J Exp Transl Clin       Date:  2018-04-27

Review 4.  Advances in spinal cord imaging in multiple sclerosis.

Authors:  Marcello Moccia; Serena Ruggieri; Antonio Ianniello; Ahmed Toosy; Carlo Pozzilli; Olga Ciccarelli
Journal:  Ther Adv Neurol Disord       Date:  2019-04-22       Impact factor: 6.570

5.  Cervical Spinal Cord Atrophy can be Accurately Quantified Using Head Images.

Authors:  Kamyar Taheri; Irene M Vavasour; Shawna Abel; Lisa Eunyoung Lee; Poljanka Johnson; Stephen Ristow; Roger Tam; Cornelia Laule; Nathalie Chantal Ackermans; Alice Schabas; Helen Cross; Jillian Katrina Chan; Ana-Luiza Sayao; Virender Bhan; Virginia Devonshire; Robert Carruthers; David Kb Li; Anthony L Traboulsee; Shannon H Kolind; Adam Vladimir Dvorak
Journal:  Mult Scler J Exp Transl Clin       Date:  2022-01-07

Review 6.  Magnetic Resonance Imaging in Primary Progressive Multiple Sclerosis Patients : Review.

Authors:  Malgorzata Siger
Journal:  Clin Neuroradiol       Date:  2022-03-08       Impact factor: 3.156

7.  Cervical and thoracic cord atrophy in multiple sclerosis phenotypes: Quantification and correlation with clinical disability.

Authors:  Yair Mina; Shila Azodi; Tsemacha Dubuche; Frances Andrada; Ikesinachi Osuorah; Joan Ohayon; Irene Cortese; Tianxia Wu; Kory R Johnson; Daniel S Reich; Govind Nair; Steven Jacobson
Journal:  Neuroimage Clin       Date:  2021-04-28       Impact factor: 4.881

8.  Spinal cord atrophy in a primary progressive multiple sclerosis trial: Improved sample size using GBSI.

Authors:  Marcello Moccia; Nicola Valsecchi; Olga Ciccarelli; Ronald Van Schijndel; Frederik Barkhof; Ferran Prados
Journal:  Neuroimage Clin       Date:  2020-09-09       Impact factor: 4.881

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.